Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Executive Summary
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
You may also be interested in...
Deal Watch: Pfizer, Biogen Partnership One Of Many As JPM Gets Underway
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Lilly Taps Loxo Execs To Bring Back That Biotech Feeling
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Need a specific report? 1000+ reports available
Buy Reports
